Close
The case for an electronic quality management system is operational. A biopharma company needs to know which document governed the work, who approved a decision, what changed, which training was current, and whether corrective action worked. A traditional QMS can answer those questions. It simply needs more human effort to do it reliably as the company grows.
The distinction matters because software itself does not make a quality system compliant. It just changes how the system controls work and how it produces evidence.
A traditional QMS is usually a mix of paper files, spreadsheets, email approvals, shared drives, and point solutions. Some parts may be digital. The defining feature is that people have to connect the records and move the workflow themselves.
An eQMS uses controlled electronic workflows and structured records for processes such as:
The useful comparison is therefore manual coordination versus system-controlled coordination.
The last point gets oversold. An eQMS does not remove administration. It moves the work into system ownership, configuration control, data stewardship, release management, and user support.
For drugs and biologics, FDA requirements remain focused on records, controls, and the underlying cGMP obligations. FDA’s Part 11 guidance explains that Part 11 applies when required records are maintained or submitted electronically, while the underlying predicate rules remain enforceable. It also identifies controls such as authorized access, operational and authority checks, training, accountability for electronic signatures, and system documentation.
FDA’s drug data-integrity guidance makes the broader point: controls should be based on risk to the patient, process, and product. ICH Q10 adds the operating model around those controls, including lifecycle management, knowledge management, quality risk management, management responsibility, process monitoring, CAPA, and change management.
None of those sources prescribes a software brand. The company remains responsible for deciding which records are regulated, how the system will control them, and how it will show that the controls work.
An eQMS earns its cost when the quality operation has outgrown human reconciliation. Common signals include:
The advantage comes from consistent structure and visible relationships. That is the part manual systems struggle to sustain at scale.
The system will expose weak process decisions because those decisions have to be configured. Teams often discover that they do not agree on:
If those questions remain open, the implementation team either delays the project or makes the decisions inside the configuration. Both routes are expensive. The second is worse because the organization may not realize the software has become its de facto policy.
A digital workflow can also preserve unnecessary approvals, duplicate reviews, and unclear handoffs. It will run the weak process consistently. That is still a weak process.
A small, early-stage company with limited GxP scope may be able to operate a disciplined manual QMS for a period of time. The test is whether the controls are clear, current, retrievable, and proportionate to risk. Buying an enterprise platform before the operating model exists can create cost without control.
The switch becomes easier to justify when one or more of these thresholds is near:
The decision should follow the company’s quality-system roadmap. Start with the processes, records, risks, owners, and expected growth. Then decide which technology is needed to control them.
The software decision is downstream of the quality-system decision. Getting that order right saves a surprising amount of money.
Kofi A. Kumi helps biopharma leaders design transformations that last. With a foundation in chemistry and a career in enterprise systems, he bridges strategy and execution across regulatory, quality, and clinical operations. His work spans top-5 pharma, mid-sized biotechs, and pre-commercial innovators, leading initiatives that have reduced procedural complexity by 80%, drove inspection readiness, and reshaped global operating models.
